SecBot SecBot

BIIB

BIOGEN INC.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0000875045 Biotech & Drug Discovery
$251.65 −1.75 (−0.69%)
Nov 16 4:00 PM ET · prev $253.40
Market cap
$37.0B
Large cap
Consensus
Buy
73% Buy or better · 44 analysts
Median target
$271.00
+8% · range $175.00–350.00
1 year
+52.8%
from $164.68 · Nov 17
30 days
+7.8%
from $233.48
52-week range
$164.42–254.87
−1% from high · low Jan 16
Avg volume 20D
1.22M
shares / day
Short interest
5.45M
≈3.7% of shares · −0.9%
Days to cover
4.0
at average volume
Insider net
−$770.7K
1 buyer · 2 sellers · since Feb 6
New fund stakes
4
Q2 2026 13F · 2 exits
Filing reports
13
analyzed by SecBot
SecBot read BULLISH 11 reports · 90 days
Balance 0 bearish · 5 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 8/11

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $585.11 at an average $195.04. 2 insiders sold $771.3K. Price is 29% above their cost.

  • InstitutionsMIXED

    Q2 2026: 47 added (4 new), 33 trimmed or exited. Largest new: Freestone Grove Partners $18.1M, D. E. Shaw & ., $16.1M.

  • AnalystsBULLISH

    32 of 44 rate it Buy or better. Median target $271.00 (+8%).

  • Short sellersSTEADY

    Short interest −0.9% to 5.45M shares. 4.0 days to cover, ≈3.7% of shares.

  • TrendUPTREND

    8% above its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 24.

Who's buying

13F· Q2 2026
4
new positions
2
exits
$59.6M
in new stakes
FundMoveSharesValue
FMR LLCADD18,217,239$3.9B
AmundiADD1,516,831$327.7M
Boston PartnersTRIM1,263,429$272.8M
UBS Group AGADD1,030,150$222.6M
CITIGROUP INCADD734,517$158.7M
ROYAL BANK OF CANADAADD708,562$153.1M
CITADEL ADVISORS LLCDOUBLED418,356$90.4M
BALYASNY ASSET MANAGEMENT L.P.TRIM265,090$57.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

44 analysts
Buy 73% rate it Buy or better
Strong Buy12Buy20Hold11Sell1Strong Sell0
12-month targets · 32 analysts

Price is inside the target range. Median implies +8%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 9, 2026Piper Sandler
REITERATE
REITERATEOverweight
Nov 2, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Nov 2, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 29, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Oct 29, 2026Argus Research
UPGRADE
UPGRADEBuy
Oct 29, 2026RBC Capital
MAINTAIN
MAINTAINOutperform

Washington

Corporate Lobbying

40 lobbying filings and 11 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$585.11
bought · 1 insider
$771.3K
sold · 2 insiders
+29.0%
vs their $195.04 cost
DateInsiderTypeValue
Oct 30, 2026
Grogan Jane
Head of Research
Oct 30, 2026
EXERCISE695 sh
Oct 30, 2026
Grogan Jane
Head of Research
Oct 30, 2026
TAX W/H$87.5K
Oct 2, 2026
Godbout Sean
Chief Accounting Officer
Oct 2, 2026
EXERCISE27 sh
Oct 2, 2026
Godbout Sean
Chief Accounting Officer
Oct 2, 2026
TAX W/H$1.8K
Oct 1, 2026
Godbout Sean
Chief Accounting Officer
Oct 1, 2026
AWARD985 sh
Sep 1, 2026
Parini Michael
Chief Legal Officer
Sep 1, 2026
AWARD7,405 sh
Aug 4, 2026
Minor Lloyd
Director
Aug 4, 2026
SELL$119.2K
Aug 3, 2026
Minor Lloyd
Director
Aug 3, 2026
SELL$120.6K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
11 drugs tracked · Drug pipeline →
Recent

Short side

FINRA· Oct 30, 2026
5,453,103
shares short
-0.9%
vs prior settlement
4.0
days to cover
≈3.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Congressional trades
BIIB trades disclosed by members of Congress, with disclosure delay.
4 members · 7 buys / 5 sells
DateMemberType AmountDisclosed
Sep 24, 2026 Maria Elvira SalazarRHouse Biogen Inc SELL $1K–$15K Oct 7, 2026 +13d
Sep 11, 2026 Ro KhannaDHouse Child account · Biogen Inc SELL $1K–$15K Oct 7, 2026 +26d
Sep 4, 2026 Ro KhannaDHouse Spouse account · Biogen Inc BUY $1K–$15K Oct 7, 2026 +33d
Aug 18, 2026 Kevin HernRHouse Biogen Inc SELL $1K–$15K Sep 1, 2026 +14d
Jun 5, 2026 Gilbert CisnerosDHouse Biogen Inc BUY $1K–$15K Jul 2, 2026 +27d
Jun 2, 2026 Maria Elvira SalazarRHouse Biogen Inc SELL $15K–$50K Jul 7, 2026 +35d
May 27, 2026 Ro KhannaDHouse Spouse account · Biogen Inc SELL $1K–$15K Jun 9, 2026 +13d
May 15, 2026 Ro KhannaDHouse Spouse account · Biogen Inc BUY $1K–$15K Jun 9, 2026 +25d
May 12, 2026 Maria Elvira SalazarRHouse Biogen Inc BUY $1K–$15K Jun 8, 2026 +27d
May 11, 2026 Maria Elvira SalazarRHouse Biogen Inc BUY $50K–$100K Jun 8, 2026 +28d

SecBot reports

13 filings · 21 press releases · 6 bullish · 0 bearish · 1 mixed · 6 neutral
All BIIB filing & press-release reports (34)